自 20 世纪 70 年代以来，意大利儿科肿瘤学家通过意大利儿科血液肿瘤学协会 (AIEOP) 网络进行合作，使用通用的集中式儿童癌症登记系统，称为模型 1.01 (Mod. 1.01)。在这项研究中，我们报告了意大利国家 AIEOP 网络中登记和治疗的儿童（0-14 岁）和青少年（15-19 岁）人口的招募趋势、区域外移民以及结果随时间的变化。 1989 年至 2017 年间。在近 30 年的时间里，Mod. 登记了 43,564 名肿瘤诊断患者的队列。 1.01。对全国区域外迁移的分析表明，患者倾向于从南方迁移到北方，也有少量迁移到中部地区。在研究期间，迁移明显减少，尤其是淋巴造血疾病，而实体瘤的迁移仍然大量。我们的数据显示，自 20 世纪 90 年代以来，诊断后 5 年的累积生存率逐渐显着增加，在过去十年中诊断的所有患者的生存率几乎达到 84%。 Mod 的存活率。 1.01 患者与显示儿童癌症监测估计的主要国家和国际报告提供的患者相似。从流行病学和卫生政策的角度来看，AIEOP Mod 1.01 已被证明是一个非常宝贵的工具，使我们能够在这项研究中检查最大的意大利儿科癌症患者的生存经历，并进行很长时间的随访。 © 2024 UICC。

Since the 1970s, Italian pediatric oncologists have collaborated through the Italian Association for Pediatric Hematology Oncology (AIEOP) network using a common centralized system for the registration of childhood cancer, known as Model 1.01 (Mod. 1.01). In this study, we report on recruitment trends, extra-regional migration and changes in outcome over time in the Italian population of children (0-14 years) and adolescents (15-19 years) registered and treated within the national AIEOP network in the period between 1989 and 2017. In almost 30 years, a cohort of 43,564 patients with a neoplasia diagnosis was registered in Mod. 1.01. The analysis of national extra-regional migration showed that patients tend to migrate from the South to the North and, to a lesser extent, to the Center of the country. During the study period, migration apparently decreased, especially for lymphohematopoietic diseases, whereas it remained substantial for solid tumors. Our data showed a progressive and significant increase in the cumulative survival 5 years after diagnosis since the 1990s, reaching almost 84% for all patients diagnosed in the last decade. Survival rates of Mod. 1.01 patients are similar to those provided by the main national and international reports showing childhood cancer surveillance estimates. The AIEOP Mod 1.01 has proved to be an invaluable tool from both an epidemiological and a health policy point of view, allowing us, in this study, to examine the survival experience of the largest cohort of Italian pediatric cancer patients with a very long follow-up.© 2024 UICC.